TY - JOUR
T1 - High intensity focused ultrasound with Focal-One® device
T2 - Prostate-specific antigen impact and morbidity evaluation during the initial experience
AU - Perez-Reggeti, J. I.
AU - Sanchez-Salas, R.
AU - Sivaraman, A.
AU - Linares Espinos, E.
AU - de Gracia-Nieto, A. E.
AU - Barret, E.
AU - Galiano, M.
AU - Rozet, F.
AU - Fregeville, A.
AU - Renard-Penna, R.
AU - Cathala, N.
AU - Mombet, A.
AU - Prapotnich, D.
AU - Cathelineau, X.
N1 - Publisher Copyright:
© 2016
PY - 2016/12/1
Y1 - 2016/12/1
N2 - Objective We report our initial experience in the treatment of prostate cancer (PCa) with high-intensity focused ultrasound (HIFU) using the Focal-One® device. Material and methods Retrospective review of the prospectively populated database. Between June 2014 to October 2015, 85 patients underwent HIFU (focal/whole-gland) treatment for localized PCa. Preoperative cancer localization was done with multiparametric magnetic resonance imaging (mpMRI) and transperineal mapping biopsies. Treatment was carried out using the Focal-One® device under general anesthesia. Oncological follow-up: PSA measurement and control biopsy with mpMRI according to protocol. Questionnaire-based functional outcome assessment was done. Complications were reported using Clavien classification. Results The median PSA was 7.79 ng/ml (IQR 6.32-9.16), with a median prostate volume of 38 cc (IQR: 33-49.75). Focal and whole-gland therapy was performed in 64 and 21 patients respectively. Ten patients received salvage HIFU. Complications were encountered in 15% of cases, all Clavien 2 graded. Mean hospital stay was 1.8 days (0-7) and bladder catheter was removed on day 2 (1-6). Mean percentage reduction of PSA was 54%. Median follow-up was 3 months (IQR: 2-8). Functional outcomes: All patients were continents at 3 months and potency was maintained in 83% of the preoperatively potent. Conclusions Focal-One® HIFU treatment appears to be a safe procedure with few complications. Functional outcomes proved no urinary incontinence and sexual function were maintained in 83%.
AB - Objective We report our initial experience in the treatment of prostate cancer (PCa) with high-intensity focused ultrasound (HIFU) using the Focal-One® device. Material and methods Retrospective review of the prospectively populated database. Between June 2014 to October 2015, 85 patients underwent HIFU (focal/whole-gland) treatment for localized PCa. Preoperative cancer localization was done with multiparametric magnetic resonance imaging (mpMRI) and transperineal mapping biopsies. Treatment was carried out using the Focal-One® device under general anesthesia. Oncological follow-up: PSA measurement and control biopsy with mpMRI according to protocol. Questionnaire-based functional outcome assessment was done. Complications were reported using Clavien classification. Results The median PSA was 7.79 ng/ml (IQR 6.32-9.16), with a median prostate volume of 38 cc (IQR: 33-49.75). Focal and whole-gland therapy was performed in 64 and 21 patients respectively. Ten patients received salvage HIFU. Complications were encountered in 15% of cases, all Clavien 2 graded. Mean hospital stay was 1.8 days (0-7) and bladder catheter was removed on day 2 (1-6). Mean percentage reduction of PSA was 54%. Median follow-up was 3 months (IQR: 2-8). Functional outcomes: All patients were continents at 3 months and potency was maintained in 83% of the preoperatively potent. Conclusions Focal-One® HIFU treatment appears to be a safe procedure with few complications. Functional outcomes proved no urinary incontinence and sexual function were maintained in 83%.
KW - Focal therapy
KW - Hemiablation
KW - High-intensity focused ultrasound
KW - Prostate cancer
UR - http://www.scopus.com/inward/record.url?scp=84992036954&partnerID=8YFLogxK
U2 - 10.1016/j.acuro.2016.04.016
DO - 10.1016/j.acuro.2016.04.016
M3 - Article
C2 - 27543259
AN - SCOPUS:84992036954
SN - 0210-4806
VL - 40
SP - 608
EP - 614
JO - Actas Urologicas Espanolas
JF - Actas Urologicas Espanolas
IS - 10
ER -